WFS1 and type 2 diabetes mellitus: have reviewed recent progress and discoveries of T2D pharmacogenetics, including GLP-1RAs, and found that GLP1R, TCF7L2, CNR1, SORCS1 and WFS1 are associated with therapeutic responses to GLP1-RAs.